Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CBC-Derived Biomarkers Associated With Recurrence After Sinus Surgery in Chronic Rhinosinusitis.

The Laryngoscope·2026
Same author

Development of a longitudinal predictive model for hepatocellular carcinoma occurrence in patients with chronic hepatitis B.

Scientific reports·2026
Same author

MitoGEx: An Integrated Platform for Streamlined Human Mitochondrial Genome Analysis.

Genes·2026
Same author

Trends in skin cancer incidence in Songkhla, Southern Thailand, 1989-2020: A population-based study on the impact of geographic variation.

PloS one·2026
Same author

Integrated Proteogenomic Approach for Discovering Potential Biomarkers in Urothelial Carcinoma of the Bladder.

Biomedicines·2025
Same author

New candidate gene mutations in astrocytoma with seizures.

Scientific reports·2025

Related Experiment Video

Updated: Jan 7, 2026

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.6K

A Patient-Derived Organoid Platform from TUR-P Samples Enables Precision Drug Screening in Advanced Prostate Cancer.

Zaukir Bostan Ali1, Mooktapa Plikomol1, Tanan Bejrananda2

  • 1Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.

Cancers
|December 30, 2025
PubMed
Summary

Researchers developed advanced prostate cancer organoids from patient tissue, improving success rates and reducing costs. These organoids accurately predict patient treatment outcomes, enabling personalized medicine decisions within a month.

Keywords:
advanced prostate cancerdrug screeningpatient derived organoids (PDOs)transurethral resection of prostate (TUR-P)

More Related Videos

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

5.6K
High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

5.9K

Related Experiment Videos

Last Updated: Jan 7, 2026

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.6K
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

5.6K
High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

5.9K

Area of Science:

  • Oncology
  • Translational Medicine
  • Biotechnology

Background:

  • Patient-derived advanced prostate cancer organoids model tumor heterogeneity and predict drug efficacy.
  • Organoids are valuable for functional drug screening and capturing patient outcomes.
  • Establishing organoids from transurethral resection of the prostate (TUR-P) specimens faces low success rates and high costs.

Purpose of the Study:

  • To enhance the success rate of establishing advanced prostate cancer organoids from TUR-P specimens.
  • To decrease the cost associated with organoid culture for clinical applications.
  • To develop a cost-effective and rapid method for personalized drug screening in prostate cancer.

Main Methods:

  • Optimization of organoid culture protocols and fetal bovine serum (FBS)-based culture medium.
  • Validation of generated organoids using histological, immunohistochemical, and genomic analyses to confirm recapitulation of tumor heterogeneity.
  • In vitro drug screening of established organoids with anti-cancer drugs (docetaxel, enzalutamide) and correlation with clinical treatments.

Main Results:

  • Achieved a successful organoid generation rate of approximately 62.07% (18 out of 29 cases) with the optimized protocol.
  • Confirmed that established organoids accurately reflect the histological, immunohistochemical, and genomic characteristics of original tumor tissues.
  • Demonstrated a positive correlation between in vitro drug screening results from organoids and actual patient clinical outcomes.

Conclusions:

  • The developed advanced prostate cancer organoids offer a reliable and cost-effective method for predicting patient treatment outcomes.
  • This approach facilitates personalized medicine by enabling timely treatment decisions within a month.
  • The study highlights the potential of improved organoid technology for clinical decision-making in advanced prostate cancer.